1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

J&J Hopes To Reach Market First For Pre-Metastatic Prostate Cancer With Apalutamide

 
• By Joseph Haas

Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours

Janssen Biotech Inc. hopes it will be first to market with a drug for non-metastatic castration-resistant prostate cancer (CRPC) with the submission of its next-generation androgen receptor inhibitor apalutamide, based on a Phase III study providing data on metastasis-free survival.

Apalutamide will be positioned in tandem with Janssen’s blockbuster prostate cancer therapy Zytiga (abiraterone acetate). "Prostate cancer is an area of focus" for Janssen and parent company Johnson & Johnson, Kiran Patel, Janssen Oncology VP for solid tumor clinical development, told Scrip

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

More from Therapy Areas

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.